{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:34:40Z","timestamp":1753893280165,"version":"3.41.2"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Surg."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Globally, gastric cancer holds the fifth position in terms of prevalence among malignant tumors and is the fourth leading cause of cancer-related mortality. Particular attention should be paid to cardia adenocarcinoma (CA) due to its increasing incidence and poor prognosis. Diagnosis of CA frequently occurs in advanced stages because of its late symptoms. In such cases, neoadjuvant chemotherapy is the primary treatment option. The response to chemotherapy depends on multiple variables including the tumor's molecular profile, the patient's performance status, and the feasibility of using targeted therapy. Patients exhibiting an exceptional response, defined as a complete response to medical therapy lasting more than 1 year, or a partial response or stable disease lasting more than 2 years, are rarely described. This case report presents one of the longest-lasting exceptional responses to chemotherapy in metastatic cardia adenocarcinoma and discusses its clinical implications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 49-year-old male patient presented with cardia adenocarcinoma (human epidermal growth factor receptor 2 negative, mismatch repair proficient) and liver metastases. Molecular profiling identified a pathogenic mutation in the TP53 gene (R123W; Arg123Trp) as the sole alteration found. Five months after initiating the neoadjuvant chemotherapy with fluorouracil\u2013leucovorin\u2013oxaliplatin\u2013docetaxel, the patient achieved a complete clinical response. The molecular profile was compared with others previously documented in an international data portal, revealing a similar pattern. At 4 years and 3 months from diagnosis, the exceptional response was still confirmed. The patient underwent a cumulative number of 33 cycles of chemotherapy, leading to chemotherapy-induced liver damage.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Exceptional responses to neoadjuvant chemotherapy in cardia adenocarcinomas are rarely reported. The documentation of exceptional responses to cancer therapies should be included in large data repositories to explore the molecular fingerprint of these tumors. In such cases, the clinical implications of long-term chemotherapy should always be taken into account.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fsurg.2024.1297083","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T04:58:37Z","timestamp":1713243517000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: The molecular fingerprint and the clinical implication of an exceptional response to neoadjuvant therapy in a metastatic cardia adenocarcinoma"],"prefix":"10.3389","volume":"11","author":[{"given":"Laura","family":"Lorenzon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Campisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Di Paolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felice","family":"Giuliante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiamma","family":"Buttitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"D\u2019Ugo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e2118457","DOI":"10.1001\/jamanetworkopen.2021.18457","article-title":"Global incidence and mortality of gastric cancer, 1980\u20132018","volume":"4","author":"Wong","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1245\/s10434-018-6627-y","article-title":"Survival trends in gastric adenocarcinoma: a population-based study in Sweden","volume":"25","author":"Asplund","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"doad006","DOI":"10.1093\/dote\/doad006","article-title":"Lymph node metastatic patterns and the development of multidisciplinary treatment for esophageal cancer","volume":"36","author":"Satoru","year":"2023","journal-title":"Dis Esophagus"},{"key":"B5","doi-asserted-by":"publisher","first-page":"855","DOI":"10.6004\/jnccn.2019.0033","article-title":"Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Ajani","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"B6","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","article-title":"Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Obermannov\u00e1","year":"2022","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1097\/SLA.0b013e318216f449","article-title":"Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adeno-carcinomas: a summary of 480 cases","volume":"253","author":"Becker","year":"2011","journal-title":"Ann Surg"},{"key":"B8","doi-asserted-by":"publisher","first-page":"106969","DOI":"10.1016\/j.ejso.2023.06.021","article-title":"Profiling complete regression after pre-operative therapy in gastric cancer patients using clinical and pathological data","volume":"49","author":"Biondi","year":"2023","journal-title":"Eur J Surg Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/onco.13600","article-title":"Molecular profiling of exceptional responders to cancer therapy","volume":"26","author":"Bilusic","year":"2021","journal-title":"Oncologist"},{"year":"","key":"B10"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1016\/0959-8049(95)00296-0","article-title":"The EORTC core quality of life questionnaire (QLQ-C30): validity and reliability when analysed with patients treated with palliative radiotherapy","author":"Kaasa","year":"1995","journal-title":"Eur J Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","article-title":"Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Lordick","year":"2022","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ejso.2015.10.016","article-title":"Surgical management of advanced gastric cancer: an evolving issue","volume":"42","author":"Marano","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ccell.2020.10.015","article-title":"Molecular features of cancers exhibiting exceptional responses to treatment","volume":"39","author":"Wheeler","year":"2021","journal-title":"Cancer Cell"},{"key":"B15","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","article-title":"The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer","volume":"600","author":"Janjigian","year":"2021","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.2217\/fon-2020-0421","article-title":"Upcoming first-line chemotherapy for HER2-negative gastric cancer in Japan: which patients benefit from immunotherapy?","volume":"16","author":"Takahari","year":"2020","journal-title":"Future Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/bjs.10663","article-title":"Meta-analysis of microsatellite instability in relation to clinicopathological characteristics and overall survival in gastric cancer","volume":"105","author":"Polom","year":"2018","journal-title":"Br J Surg"},{"key":"B18","doi-asserted-by":"publisher","first-page":"6601","DOI":"10.1007\/s00432-023-04636-y","article-title":"Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO study","volume":"149","author":"Nappo","year":"2023","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Frontiers in Surgery"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2024.1297083\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T04:58:39Z","timestamp":1713243519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsurg.2024.1297083\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,16]]},"references-count":18,"alternative-id":["10.3389\/fsurg.2024.1297083"],"URL":"https:\/\/doi.org\/10.3389\/fsurg.2024.1297083","relation":{},"ISSN":["2296-875X"],"issn-type":[{"type":"electronic","value":"2296-875X"}],"subject":[],"published":{"date-parts":[[2024,4,16]]},"article-number":"1297083"}}